Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Polymyxin b sulfate and trimethoprim sulfate

Also listed by the FDA as: polymyxin b sulfate / trimethoprim sulfate · polymyxin b sulfate / trimethoprim

Drug class: Dihydrofolate Reductase Inhibitor Antibacterial

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Polymyxin b sulfate and trimethoprim sulfate key facts

Drug class
Dihydrofolate Reductase Inhibitor Antibacterial
Used for
Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms … (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$0.4507 per mL (polymyxin b sulfate 10000 USP units/mL · trimethoprim sulfate 1 mg/mL; NADAC)
Latest FDA recall
None listed

Sources: FDA label (August 17, 2026); FDA NDC Directory (October 30, 2026); CMS NADAC (November 4, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Polymyxin b sulfate and trimethoprim sulfate used for?
The FDA-approved label (Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., August 17, 2026) says: “Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Polymyxin b sulfate and trimethoprim sulfate?
The “Adverse Reactions” section of the FDA label (Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., August 17, 2026) begins: “The most frequent adverse reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Polymyxin b sulfate and trimethoprim sulfate have a boxed warning?
No. None of the 14 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Polymyxin b sulfate and trimethoprim sulfate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Polymyxin b sulfate and trimethoprim sulfate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Polymyxin b sulfate and trimethoprim sulfate?
10 companies list prescription products of Polymyxin b sulfate and trimethoprim sulfate in the FDA NDC Directory, including Proficient Rx LP, NuCare Pharmaceuticals, Inc. and Remedyrepack Inc.

What Polymyxin b sulfate and trimethoprim sulfate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. …

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (solution, ophthalmic), Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 14 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 14 FDA labels for this medicine have a boxed warning.

Polymyxin b sulfate and trimethoprim sulfate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The most frequent adverse reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash.

Read more of this section

Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and anaphylaxis have been reported. Photosensitivity has been reported in patients taking oral trimethoprim. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

Polymyxin b sulfate and trimethoprim sulfate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

Polymyxin b sulfate and trimethoprim sulfate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Teratogenic Effects Animal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Trimethoprim has been shown to be teratogenic in the rat when given in oral doses 40 times the human dose.

Read more of this section

In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with oral doses 6 times the human therapeutic dose. While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or oral trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter. Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

Polymyxin b sulfate and trimethoprim sulfate and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is administered to a nursing woman.

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

When Polymyxin b sulfate and trimethoprim sulfate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.

— FDA label: Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsSolution · Solution/ drops
RouteOphthalmic
Prescription products14 in the FDA NDC Directory

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Polymyxin b sulfate and trimethoprim sulfate, by strength and form
Strength and formGeneric or brandPharmacies pay
polymyxin b sulfate 10000 USP units/mL · trimethoprim sulfate 1 mg/mL
solution
Generic $0.4507 per mL
polymyxin b sulfate 10000 USP units/mL · trimethoprim sulfate 1 mg/mL
solution/ drops
Generic $0.4507 per mL
polymyxin b sulfate 10000 units/mL · trimethoprim 1 mg/mL
solution/ drops
Generic $0.4507 per mL

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.

Generic approvals (4)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)244967
SPL set ID of the quoted label65293418-c6ad-43d8-948c-e1949c0afc31
FDA labels (SPL)14
FDA applications4 ANDA
Active ingredients (FDA)POLYMYXIN B / TRIMETHOPRIM

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Polymyxin B Sulfate and Trimethoprim, Preferred Pharmacetucials Inc., effective August 17, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers